Press & Blog
The latest developments from Nerbio Medical Software Platforms Inc.
Introducing iTOF 2.0: The Next Generation in Neuromuscular Monitoring
Nerbio is proud to announce the release of iTOF 2.0, the latest version of our FDA-cleared, app-controlled neuromuscular blockade (NMB) monitoring system. This new iteration builds upon the foundational capabilities of iTOF, incorporating advanced features designed to enhance clinical efficiency, patient safety, and user experience.What’s New in iTOF 2.0
Real-Time Trend Plots
iTOF 2.0 introduces dynamic trend plots that visualize neuromuscular function over time. These plots provide clinicians with immediate insights into the patient’s response to neuromuscular blocking agents, facilitating timely adjustments and informed decision-making.
Comprehensive Case Records
The updated app now allows for the creation, management and sharing of detailed case records. Clinicians can document patient information, drug dosages, and monitoring data within a single interface, ensuring thorough documentation and streamlined workflows.
Enhanced Setup Information
iTOF 2.0 offers improved setup screens that guide clinicians through the configuration process. These enhancements simplify the setup of patient parameters and drug types, reducing setup time and minimizing the potential for errors.
AI-Powered Assistance
Leveraging advanced AI modeling, the iTOF AI Assistant provides contextual, voice- and text-based guidance. This feature offers real-time support, interactive training videos, and instant answers to user queries, empowering clinicians with actionable insights at the point of care.
Seamless Workflow Integration
Designed for versatility, iTOF 2.0 incorporates wireless operation with Bluetooth connectivity, allowing for remote monitoring across various perioperative settings. The app’s intuitive interface and integration with the Nerbio iCARE™ Platform ensure a cohesive experience from induction through recovery.
Proven Impact in Clinical Settings
Hospitals utilizing iTOF have reported significant improvements in operational efficiency and patient outcomes:- 10% increase in operating room throughput
- 30% reduction in the use of neuromuscular blockers and reversal agents
- 70% decrease in residual blockade complications
These enhancements align with the American Society of Anesthesiologists (ASA) guidelines, underscoring iTOF’s commitment to safety and efficacy in neuromuscular monitoring.